The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | CRB-401: ide-cel for R/R multiple myeloma
Idecabtagene Vicleucel (ide-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets the B-cell maturation antigen (BCMA). In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the Phase I CRB-401 (NCT02658929) study, a non-randomized, open-label, multi-site study of idecabtagene vicleucel in adults with relapsed/refractory (R/R) multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultant: Kite/Gilead, Celgene/BMS, JUNO/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Iovance, Takeda, Fosun Kite
Grant/Research Support: Kite/Gilead, Celgene, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda, Boston Scientific
Data safety monitoring board: Sorrento
All funds paid to Mayo Clinic, no personal compensation.
